Cargando…

Predicting frequent asthma exacerbations using blood eosinophil count and other patient data routinely available in clinical practice

PURPOSE: Acute, severe asthma exacerbations can be difficult to predict and thus prevent. Patients who have frequent exacerbations are of particular concern. Practical exacerbation predictors are needed for these patients in the primary-care setting. PATIENTS AND METHODS: Medical records of 130,547...

Descripción completa

Detalles Bibliográficos
Autores principales: Price, David, Wilson, Andrew M, Chisholm, Alison, Rigazio, Anna, Burden, Anne, Thomas, Michael, King, Christine
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4708874/
https://www.ncbi.nlm.nih.gov/pubmed/26793004
http://dx.doi.org/10.2147/JAA.S97973
_version_ 1782409564511010816
author Price, David
Wilson, Andrew M
Chisholm, Alison
Rigazio, Anna
Burden, Anne
Thomas, Michael
King, Christine
author_facet Price, David
Wilson, Andrew M
Chisholm, Alison
Rigazio, Anna
Burden, Anne
Thomas, Michael
King, Christine
author_sort Price, David
collection PubMed
description PURPOSE: Acute, severe asthma exacerbations can be difficult to predict and thus prevent. Patients who have frequent exacerbations are of particular concern. Practical exacerbation predictors are needed for these patients in the primary-care setting. PATIENTS AND METHODS: Medical records of 130,547 asthma patients aged 12–80 years from the UK Optimum Patient Care Research Database and Clinical Practice Research Datalink, 1990–2013, were examined for 1 year before (baseline) and 1 year after (outcome) their most recent blood eosinophil count. Baseline variables predictive (P<0.05) of exacerbation in the outcome year were compared between patients who had two or more exacerbations and those who had no exacerbation or only one exacerbation, using uni- and multivariable logistic regression models. Exacerbation was defined as asthma-related hospital attendance/admission (emergency or inpatient) or acute oral corticosteroid (OCS) course. RESULTS: Blood eosinophil count >400/µL (versus ≤400/µL) increased the likelihood of two or more exacerbations >1.4-fold (odds ratio [OR]: 1.48 (95% confidence interval [CI]: 1.39, 1.58); P<0.001). Variables that significantly increased the odds by up to 1.4-fold included increasing age (per year), female gender (versus male), being overweight or obese (versus normal body mass index), being a smoker (versus nonsmoker), having anxiety/depression, diabetes, eczema, gastroesophageal reflux disease, or rhinitis, and prescription for acetaminophen or nonsteroidal anti-inflammatory drugs. Compared with treatment at British Thoracic Society step 2 (daily controller ± reliever), treatment at step 0 (none) or 1 (as-needed reliever) increased the odds by 1.2- and 1.6-fold, respectively, and treatment at step 3, 4, or 5 increased the odds by 1.3-, 1.9-, or 3.1-fold, respectively (all P<0.05). Acute OCS use was the single best predictor of two or more exacerbations. Even one course increased the odds by more than threefold (OR: 3.75 [95% CI: 3.50, 4.01]; P<0.001), and three or more courses increased the odds by >25-fold (OR: 25.7 [95% CI: 23.9, 27.6]; P<0.001). CONCLUSION: Blood eosinophil count and several other variables routinely available in patient records may be used to predict frequent asthma exacerbations.
format Online
Article
Text
id pubmed-4708874
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-47088742016-01-20 Predicting frequent asthma exacerbations using blood eosinophil count and other patient data routinely available in clinical practice Price, David Wilson, Andrew M Chisholm, Alison Rigazio, Anna Burden, Anne Thomas, Michael King, Christine J Asthma Allergy Original Research PURPOSE: Acute, severe asthma exacerbations can be difficult to predict and thus prevent. Patients who have frequent exacerbations are of particular concern. Practical exacerbation predictors are needed for these patients in the primary-care setting. PATIENTS AND METHODS: Medical records of 130,547 asthma patients aged 12–80 years from the UK Optimum Patient Care Research Database and Clinical Practice Research Datalink, 1990–2013, were examined for 1 year before (baseline) and 1 year after (outcome) their most recent blood eosinophil count. Baseline variables predictive (P<0.05) of exacerbation in the outcome year were compared between patients who had two or more exacerbations and those who had no exacerbation or only one exacerbation, using uni- and multivariable logistic regression models. Exacerbation was defined as asthma-related hospital attendance/admission (emergency or inpatient) or acute oral corticosteroid (OCS) course. RESULTS: Blood eosinophil count >400/µL (versus ≤400/µL) increased the likelihood of two or more exacerbations >1.4-fold (odds ratio [OR]: 1.48 (95% confidence interval [CI]: 1.39, 1.58); P<0.001). Variables that significantly increased the odds by up to 1.4-fold included increasing age (per year), female gender (versus male), being overweight or obese (versus normal body mass index), being a smoker (versus nonsmoker), having anxiety/depression, diabetes, eczema, gastroesophageal reflux disease, or rhinitis, and prescription for acetaminophen or nonsteroidal anti-inflammatory drugs. Compared with treatment at British Thoracic Society step 2 (daily controller ± reliever), treatment at step 0 (none) or 1 (as-needed reliever) increased the odds by 1.2- and 1.6-fold, respectively, and treatment at step 3, 4, or 5 increased the odds by 1.3-, 1.9-, or 3.1-fold, respectively (all P<0.05). Acute OCS use was the single best predictor of two or more exacerbations. Even one course increased the odds by more than threefold (OR: 3.75 [95% CI: 3.50, 4.01]; P<0.001), and three or more courses increased the odds by >25-fold (OR: 25.7 [95% CI: 23.9, 27.6]; P<0.001). CONCLUSION: Blood eosinophil count and several other variables routinely available in patient records may be used to predict frequent asthma exacerbations. Dove Medical Press 2016-01-07 /pmc/articles/PMC4708874/ /pubmed/26793004 http://dx.doi.org/10.2147/JAA.S97973 Text en © 2016 Price et al. This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution – Non Commercial (unported, v3.0) License The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed.
spellingShingle Original Research
Price, David
Wilson, Andrew M
Chisholm, Alison
Rigazio, Anna
Burden, Anne
Thomas, Michael
King, Christine
Predicting frequent asthma exacerbations using blood eosinophil count and other patient data routinely available in clinical practice
title Predicting frequent asthma exacerbations using blood eosinophil count and other patient data routinely available in clinical practice
title_full Predicting frequent asthma exacerbations using blood eosinophil count and other patient data routinely available in clinical practice
title_fullStr Predicting frequent asthma exacerbations using blood eosinophil count and other patient data routinely available in clinical practice
title_full_unstemmed Predicting frequent asthma exacerbations using blood eosinophil count and other patient data routinely available in clinical practice
title_short Predicting frequent asthma exacerbations using blood eosinophil count and other patient data routinely available in clinical practice
title_sort predicting frequent asthma exacerbations using blood eosinophil count and other patient data routinely available in clinical practice
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4708874/
https://www.ncbi.nlm.nih.gov/pubmed/26793004
http://dx.doi.org/10.2147/JAA.S97973
work_keys_str_mv AT pricedavid predictingfrequentasthmaexacerbationsusingbloodeosinophilcountandotherpatientdataroutinelyavailableinclinicalpractice
AT wilsonandrewm predictingfrequentasthmaexacerbationsusingbloodeosinophilcountandotherpatientdataroutinelyavailableinclinicalpractice
AT chisholmalison predictingfrequentasthmaexacerbationsusingbloodeosinophilcountandotherpatientdataroutinelyavailableinclinicalpractice
AT rigazioanna predictingfrequentasthmaexacerbationsusingbloodeosinophilcountandotherpatientdataroutinelyavailableinclinicalpractice
AT burdenanne predictingfrequentasthmaexacerbationsusingbloodeosinophilcountandotherpatientdataroutinelyavailableinclinicalpractice
AT thomasmichael predictingfrequentasthmaexacerbationsusingbloodeosinophilcountandotherpatientdataroutinelyavailableinclinicalpractice
AT kingchristine predictingfrequentasthmaexacerbationsusingbloodeosinophilcountandotherpatientdataroutinelyavailableinclinicalpractice